Positive News SentimentPositive NewsNASDAQ:ANEB Anebulo Pharmaceuticals (ANEB) Stock Forecast, Price & News $2.38 +0.02 (+0.85%) (As of 05/26/2023 08:46 PM ET) Add Compare Share Share Today's Range$2.38▼$2.3850-Day Range$2.06▼$2.9852-Week Range$1.77▼$7.00Volume700 shsAverage Volume5,120 shsMarket Capitalization$61.00 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Anebulo Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside194.1% Upside$7.00 Price TargetShort InterestHealthy0.09% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.48) to ($0.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.21 out of 5 starsMedical Sector409th out of 1,010 stocksPharmaceutical Preparations Industry188th out of 494 stocks 3.5 Analyst's Opinion Consensus RatingAnebulo Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Anebulo Pharmaceuticals has a forecasted upside of 194.1% from its current price of $2.38.Amount of Analyst CoverageAnebulo Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.09% of the float of Anebulo Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAnebulo Pharmaceuticals has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Anebulo Pharmaceuticals has recently decreased by 18.64%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAnebulo Pharmaceuticals does not currently pay a dividend.Dividend GrowthAnebulo Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANEB. Previous Next 2.7 News and Social Media Coverage News SentimentAnebulo Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Anebulo Pharmaceuticals this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anebulo Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders85.70% of the stock of Anebulo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 26.70% of the stock of Anebulo Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Anebulo Pharmaceuticals are expected to decrease in the coming year, from ($0.48) to ($0.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anebulo Pharmaceuticals is -5.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anebulo Pharmaceuticals is -5.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnebulo Pharmaceuticals has a P/B Ratio of 4.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Anebulo Pharmaceuticals (NASDAQ:ANEB) StockAnebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. The company was incorporated in 2020 and is based in Lakeway, Texas.Read More Receive ANEB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ANEB Stock News HeadlinesMay 19, 2023 | finance.yahoo.comDown -26.43% in 4 Weeks, Here's Why You Should You Buy the Dip in Anebulo Pharmaceuticals, Inc. (ANEB)May 18, 2023 | msn.comBenchmark Reiterates Anebulo Pharmaceuticals (ANEB) Speculative Buy RecommendationMay 29, 2023 | Stocks To Trade (Ad)15 A.I. Trading Opportunities a DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 16, 2023 | americanbankingnews.comShort Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Decreases By 9.2%May 11, 2023 | finanznachrichten.deAnebulo Pharmaceuticals, Inc.: Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent UpdatesMay 11, 2023 | msn.comAnebulo Pharmaceuticals: Q3 Earnings InsightsMay 11, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent UpdatesMay 1, 2023 | americanbankingnews.comAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest UpdateMay 29, 2023 | Stocks To Trade (Ad)15 A.I. Trading Opportunities a DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.April 16, 2023 | americanbankingnews.comAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Up 460.0% in MarchMarch 29, 2023 | msn.comAntidote For THC? Anebulo Releases Positive Clinical Data Showing Potential Of Its Drug For Treatment Of Acute Cannabinoid IntoxicationMarch 28, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid IntoxicationMarch 8, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Expands its Integrated and Outsourced SolutionsFebruary 19, 2023 | barrons.comAnebulo Pharmaceuticals Inc.February 10, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent UpdatesJanuary 27, 2023 | seekingalpha.comAnebulo: Interesting Drug For Cannabis Intoxication, But The Market Potential Remains UnclearJanuary 9, 2023 | msn.comAcute Cannabinoid Intoxication: This Pharma Company's Clinical Trials To Reduce And Treat SymptomsJanuary 9, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid IntoxicationDecember 21, 2022 | finance.yahoo.comCompanies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In GrowthNovember 10, 2022 | finance.yahoo.comAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent UpdatesNovember 1, 2022 | finance.yahoo.comAnebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of DirectorsSeptember 26, 2022 | finance.yahoo.comLower Doses Of Anebulo's ANEB-001 Reduces Negative Effects Of Higher Doses Of THCSeptember 26, 2022 | finance.yahoo.comAnebulo Pharmaceuticals Announces $6.6 Million Private Placement FinancingSeptember 26, 2022 | finance.yahoo.comAnebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid IntoxicationSeptember 20, 2022 | finance.yahoo.comAnebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022September 10, 2022 | investing.comAnebulo Pharmaceuticals Earnings Miss, Revenue Inline In Q1September 10, 2022 | seekingalpha.comAnebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ANEB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ANEB Company Calendar Last Earnings11/12/2021Today5/28/2023Fiscal Year End6/30/2023Next Earnings (Estimated)9/08/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANEB CUSIPN/A CIK1815974 Webwww.anebulo.com Phone512-598-0931FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$8.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+194.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,830,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-73.82% Return on Assets-69.31% Debt Debt-to-Equity RatioN/A Current Ratio9.68 Quick Ratio9.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book4.76Miscellaneous Outstanding Shares25,630,000Free Float3,666,000Market Cap$61.00 million OptionableNot Optionable Beta-1.42 Key ExecutivesDr. Joseph F. Lawler M.D. (Age 50)Ph.D., Founder & Chairman Comp: $11kMr. Simon J. Allen B.Sc. (Age 54)M.B.A., MBA, CEO & Director Comp: $450kMr. Rex Merchant CFA (Age 62)CFO & Sec. Comp: $275kDr. Kenneth C. Cundy Ph.D. (Age 63)Chief Scientific Officer Comp: $345.53kMr. Scott L. AndersonHead of Investor Relations & Public AffairsKey CompetitorsHomology MedicinesNASDAQ:FIXXHepion PharmaceuticalsNASDAQ:HEPAAdageneNASDAQ:ADAGConnect BiopharmaNASDAQ:CNTBGain TherapeuticsNASDAQ:GANXView All Competitors ANEB Stock - Frequently Asked Questions Should I buy or sell Anebulo Pharmaceuticals stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anebulo Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANEB shares. View ANEB analyst ratings or view top-rated stocks. What is Anebulo Pharmaceuticals' stock price forecast for 2023? 2 Wall Street analysts have issued 1-year price objectives for Anebulo Pharmaceuticals' shares. Their ANEB share price forecasts range from $6.00 to $8.00. On average, they predict the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 194.1% from the stock's current price. View analysts price targets for ANEB or view top-rated stocks among Wall Street analysts. How have ANEB shares performed in 2023? Anebulo Pharmaceuticals' stock was trading at $2.4237 at the beginning of the year. Since then, ANEB stock has decreased by 1.8% and is now trading at $2.38. View the best growth stocks for 2023 here. When is Anebulo Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, September 8th 2023. View our ANEB earnings forecast. How were Anebulo Pharmaceuticals' earnings last quarter? Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.04. When did Anebulo Pharmaceuticals IPO? (ANEB) raised $21 million in an IPO on Friday, May 7th 2021. The company issued 3,000,000 shares at a price of $6.00-$8.00 per share. The Benchmark Company served as the underwriter for the IPO. What is Anebulo Pharmaceuticals' stock symbol? Anebulo Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANEB." How do I buy shares of Anebulo Pharmaceuticals? Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Anebulo Pharmaceuticals' stock price today? One share of ANEB stock can currently be purchased for approximately $2.38. How much money does Anebulo Pharmaceuticals make? Anebulo Pharmaceuticals (NASDAQ:ANEB) has a market capitalization of $61.00 million. The company earns $-6,830,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. How can I contact Anebulo Pharmaceuticals? The official website for the company is www.anebulo.com. The company can be reached via phone at 512-598-0931 or via email at ybriggs@lhai.com. This page (NASDAQ:ANEB) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.